Claims for Patent: 7,335,761

Summary for Patent: 7,335,761

Title:	Avian gene expression controlling regions
Abstract:	The present invention includes avian ovomucoid gene expression controlling regions which may be operably linked to one or more useful amino acid coding sequences.
Inventor(s):	Harvey; Alex J. (Athens, GA), Leavitt; Markley C. (Watkinsville, GA), Wang; Youliang (Monroe, GA)
Assignee:	AviGenics, Inc. (Athens, GA)
Application Number:	11/047,184
Patent Claims:	1. A nucleic acid molecule comprising an ovomucoid gene expression controlling region having a sequence at least 95% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 2. The nucleic acid molecule of claim 1 wherein the nucleic acid is DNA. 3. The nucleic acid molecule of claim 1 comprising an attB site. 4. The nucleic acid molecule of claim 1 comprising a signal sequence coding region. 5. The nucleic acid molecule of claim 1 comprising an IRES. 6. The nucleic acid molecule of claim 1 comprising a vector. 7. The nucleic acid molecule of claim 6 wherein the vector is selected from the group consisting of a plasmid and a viral vector. 8. The nucleic acid molecule of claim 1 comprising an artificial chromosome. 9. The nucleic acid of claim 1 wherein the ovomucoid gene expression controlling region comprises a sequence at least 99% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 10. The nucleic acid of claim 1 wherein the ovomucoid gene expression controlling region comprises a nucleic acid sequence consisting of the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 11. The nucleic acid molecule of claim 1 wherein a nucleotide sequence encoding a portion of light chain or portion of a heavy chain of an antibody is operably linked to the ovomucoid gene expression controlling region. 12. The nucleic acid molecule of claim 11 wherein the antibody is selected from the group consisting of IgG, IgA, IgD, IgM and IgE. 13. The nucleic acid molecule of claim 11 wherein the antibody is IgG. 14. The nucleic acid molecule of claim 11 wherein the antibody is IgG1. 15. The nucleic acid molecule of claim 1 wherein a nucleotide sequence encoding a hormone is operably linked to the ovomucoid gene expression controlling region. 16. A nucleic acid molecule comprising an ovomucoid gene expression controlling region having a sequence 95% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement operably linked to a coding sequence encoding an amino acid sequence other than ovomucoid. 17. The nucleic acid of claim 16 wherein the ovomucoid gene expression controlling region comprises a sequence at least 99% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 18. The nucleic acid of claim 16 wherein the ovomucoid gene expression controlling region comprises a nucleic acid sequence consisting of the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 19. A nucleic acid molecule comprising an ovomucoid gene expression controlling region isolated from a chicken comprising a sequence at least 95% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement and a coding sequence encoding an amino acid sequence of a therapeutic protein. 20. The nucleic acid molecule of claim 19 wherein the therapeutic protein is selected from the group consisting of Factor VIII, B-domain deleted Factor VIII, Factor VIIa; Factor IX, anticoagulant; hirudin, Alteplase, tPA, tPA--3 of 5 domains deleted, insulin, insulin aspart, insulin glargine, rhGH, glucagons, TSH, follitropin-beta FSH, GM-CSF, PDGH, hormones, cytokines, IFN alpa2a, INF-apha, IFN alpa2b, EPO, G-CSF, GM-CSF, INF-beta 1b, IFN-beta 1a, IFN-gamma1b, IL-2, IL-11, HBsAg, HBsAgn and OspA. 21. The nucleic acid of claim 19 wherein the ovomucoid gene expression controlling region comprises a sequence at least 99% identical to the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 22. The nucleic acid of claim 19 wherein the ovomucoid gene expression controlling region comprises a nucleic acid sequence consisting of the nucleotide sequence of nucleotides 34,473 to 36,248 of SEQ ID NO: 36 or its complement. 23. The nucleic acid molecule of claim 19 wherein the therapeutic protein is selected from the group consisting of murine MAb directed against t-lymphocyte antigen CD3, murine MAb directed against TAG-72, tumor-associated glycoprotein , FAb fragments derived from chimeric MAb directed against platelet surface receptor GPII(b)/III(a), murine MAb fragment directed against tumor-associated antigen CA125, murine MAb fragment directed against human carcinoembryonic antigen, CEA, murine MAb fragment directed against human cardiac myosin, murine MAb fragment directed against tumor surface antigen PSMA, murine MAb fragments (FAb/FAb2 mix) directed against HMW-MAA, murine MAb fragment (FAb) directed against carcinoma-associated antigen, MAb fragments (FAb) directed against NCA 90, a surface granulocyte nonspecific cross reacting antigen, chimeric MAb directed against CD20 antigen found on surface of B lymphocytes, humanized MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against TNF-alpha, humanized MAb directed against an epitope on the surface of respiratory synctial virus, humanized MAb directed against HER 2, human epidermal growth factor receptor 2, human MAb directed against cytokeratin tumor-associated antigen, anti-CTLA4, chimeric MAb directed against CD 20 surface antigen of B lymphocytes, dornase-alpha DNAse, beta glucocerebrosidase, TNF-alpha, IL-2-diptheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, TNFR-1gG fragment fusion protein, enbrel, laronidase, teriparatide and parathyroid hormone derivatives.

Details for Patent 7,335,761

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	FOLLISTIM	follitropin beta	For Injection	020582	09/29/1997		2021-11-30
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/20/2000		2021-11-30
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/25/2007		2021-11-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	FOLLISTIM AQ CARTRIDGE	follitropin beta	Injection	021211	03/23/2004		2021-11-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	FOLLISTIM AQ CARTRIDGE	follitropin beta	Injection	021211	02/11/2005		2021-11-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	FOLLISTIM AQ	follitropin beta	Injection	021273	08/26/2005		2021-11-30